Although several drugs are under investigation, there are currently no approved drugs for NAFLD ( The pathogenetic role of oxidative stress in NALFD is well known and would explain the rationale for the use of GSH as a potential therapy
But, its vital to note the difference between animal studies and human health
Most likely, the prescription is being filled through CVS Specialty
The main mechanisms of cardiovascular protection by GLP-1RA are currently explored as follows: anti-inflammatory, anti-atherosclerosis, reduction of reactive oxygen species production and anti-oxidative stress, reduction of thrombotic events, etc
Starting July 1, 2026, eligible Humana MAPD members may access Wegovy (injection or tablet) and Zepbound (KwikPen) through the Medicare GLP-1 Bridge at a $50 monthly copayment